Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH) and Other Histiocytic Disorders

  • End date
    Dec 11, 2029
  • participants needed
  • sponsor
    Carl Allen
Updated on 11 September 2021


This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.


Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) arises from blood cells that receive incorrect growth signals. These incorrect signals are caused by changes in genes (mutations) that lead to tissue damage (lesions) which causes disease. Some patients with LCH can develop neurodegeneration (LCH-ND) which is damage to neurons that results in reduced brain function, from LCH cells that go to the brain and activate inflammation. LCH arises from blood cells that receive incorrect growth signals. These incorrect signals are caused by mutations (changes in genes). The LCH blood cells can create changes in the structure of almost any organ, and can cause damage to normal organ function.

The purpose of this research study is to learn whether cobimetinib is safe and effective in subjects diagnosed with LCH, LCH-ND, RDD, JXG and ECD which may have a specfic mutation called BRAF-V600E. In healthy cells, certain proteins (called BRAF and MEK) are thought to help control normal cell growth. BRAF-V600E is a specific change in a gene that may cause cancer cells to grow and spread by sending constant signals to the MEK protein. Cobimetinib is designed to attach to and block the activity of MEK.

Condition Neuro-Degenerative Disease, Nevoxanthoendothelioma, Malignant histiocytosis, Sinus histiocytosis, Dermatosis, Congenital Skin Diseases, Erdheim-Chester Disease, histiocytosis x, Skin Conditions, Histiocytic Disorders, Malignant, langerhans cell histiocytosis
Treatment Cobimetinib
Clinical Study IdentifierNCT04079179
SponsorCarl Allen
Last Modified on11 September 2021


Yes No Not Sure

Inclusion Criteria

For Group 1: Participant must be less than 30 years of age at the time of enrollment
For Group 2: Participant may be any age at the time of enrollment
For Group 3: Participant must be less than 30 years of age at the time of enrollment
For Group 4: Participant must be 30 years of age or older at the time of enrollment
Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet which may be taken by mouth or other enteral route such as nasogastric or gastric tube
Biopsy proven LCH -AND
Failure of at least front-line therapy for high-risk LCH with evaluable disease. -OR
Failure of at least second-line therapy for low-risk LCH with evaluable disease. -OR
Diagnosis of LCH-associated neurodegenerative disease with radiologic or clinical progression within the past 3 months. -OR
Biopsy proven JXG, ECD, RDD, histiocytic sarcoma, or other histiocytic lesion (newly diagnosed or relapsed/refractory disease) with evaluable active disease
Performance Level
Karnofsky 50% for patients > 16 years of age and Lansky 50% for patients 16 years of age
Adequate Hematologic Function Defined as
ANC 0.75 x 10^9/L (unsupported/without growth factor stimulant)
Platelet count 75 x 10^9/L (unsupported/without transfusion within the past 7 days)
Patients with marrow disease must have platelet count of >/= 75 x 10^9/L (transfusion support allowed) and must not be refractory to platelet transfusions
Hemoglobin 8 g/dL (unsupported/without transfusion within the past 7 days)
Patients with marrow disease must have hemoglobin 8 g/dL (transfusion support allowed)
Adequate Renal Function Defined as
Calculated creatinine clearance (or radioisotope GFR) 70 mL/min/1.73m^2 or serum creatinine based on age/gender as follows
Maximum Serum Creatinine (mg/dL) Age 2 to < 6 years: Male 0.8 mg/d, Female
8; 6 to < 10 years: Male 1 mg/dL,Female 1; 10 to < 13 years: Male 1.2 mg/dL
Female 1.2; 13 to < 16 years: Male 1.5 mg/dL ; Female 1.4
years: Male 1.7 mg/dL; Female 1.4
Adequate Liver Function Defined as
Bilirubin (sum of conjugated + unconjugated) 1.5 x upper limit of normal (ULN) for age
AST and ALT 2.5x ULN for age
Serum albumin 2 g/dL
For patients with liver disease caused by histiocytic disorder
Patients may be enrolled with abnormal bilirubin, AST, ALT and albumin with
documentation of histiocytic liver disease
Adequate Cardiac Function Defined as
Fractional shortening (FS) of 30% or ejection fraction of 50% by echocardiogram at baseline, as determined by echocardiography or multigated acquisition scan (MUGA) within 21 days prior to study database registration. Depending on institutional standard, either FS or LVEF is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above
Female patients of childbearing potential require a negative urine or serum pregnancy test for eligibility and again at database registration, if more than 2 weeks has elapsed
Female patients of childbearing potential must agree to follow the contraceptive requirements using two forms of effective contraceptive methods for the duration of the study treatment

Exclusion Criteria

Prior and Concomitant Use of Drugs with CYP3A4 inducing/inhibiting activity: Patient taking strong inducers or inhibitors of CYP3A4 within 14 days prior to study enrollment, including but not limited to the following: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort
Prior Therapy Restrictions Completion of previous chemotherapy, immunotherapy, radiotherapy, or targeted therapy for LCH (or other histiocytic disorder) at least 28 days (except where specified below) prior to study database registration, with resolution of all associated toxicity to Grade 1 prior to study enrollment (exception for alopecia and ototoxicity which do not need to be resolved Grade 1). Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the laboratory eligibility criteria are met, the patient is considered to have recovered adequately
Radiation therapy within the last 28 days
Any prior treatment with Cobimetinib
Treatment with a long-acting hematopoietic growth factor within 14 days prior to initiation of study drug or a short-acting hematopoietic growth factor within 7 days prior to database registration
Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives), immunotherapy, biologic therapy, investigational therapy, or herbal cancer therapy within 28 days or < 5 half-lives, whichever is longer, prior to database registration
Treatment with high-dose chemotherapy and stem-cell rescue (autologous stem cell transplant) or allogeneic stem cell transplant within 90 days prior to study database registration. Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
For patients with brain tumors (intracranial masses), use of anticoagulants within 7 days prior to study database registration
Corticosteroid therapy <0.5 mg/kg/day averaged during the month prior to study database registration is permissible but must be discontinued fourteen (14) days prior to prior to study database registration. Patients with documented brain lesions receiving corticosteroids for management of cerebral edema must be on a stable dose for fourteen (14) days prior to study database registration
Patient has received treatment with investigational therapy within 4 weeks prior to initiation of study drug
Exclusions for other illness
Other active malignancy or history of secondary malignancy
Refractory nausea and vomiting, malabsorption, external biliary shunt
Infection: Patients who have a known active infection (excluding documented fungal infection of the nail beds) within 28 days prior to study database registration that has not completely resolved
Major surgical procedure or significant traumatic injury within 28 days prior to study database registration, or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device or minor surgery is permitted within fourteen (14) days of study enrollment (provided that the wound has healed)
History of significant bowel resection that would preclude adequate absorption or other significant malabsorptive disease
History of pneumonitis
Ophthalmologic considerations: Patients with known significant ophthalmologic conditions or known risk factors for retinal vein occlusion are not eligible. Specifically, patients with a history of retinal vein occlusion (RVO), retinal detachment, retinal pathology on ophthalmologic exam, retinopathy of prematurity, central serous chorioretinopathy (CSSCR), neovascular retinopathy, intraocular pressure > 21 mmHg, and predisposing factors to RVO (e.g., uncontrolled hypertension, diabetes, or hyperlipidemia, coagulopathy) will be excluded. Patients with longstanding and stable ophthalmologic findings secondary to existing conditions are eligible with appropriate documentation and approval from Study (Co)Chair and Coordinating Center
History of solid organ transplantation: Patients who have received a prior solid organ transplantation are not eligible
Any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator contraindicates use of an investigational drug or places the patient at unacceptable risk from treatment complications
History of clinically significant cardiac dysfunction, including the following
Clinically significant cardiac arrhythmias including brady-arrhythmias and/or patients who require anti-arrhythmic therapy (with the exception of beta blockers or digoxin). Patients with controlled atrial fibrillation are not excluded
Unstable arrhythmia
Unstable angina, or new-onset angina within 3 months prior to initiation of study treatment
Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher
Myocardial infarction within 3 months prior to initiation of study treatment
Known chronic human immunodeficiency virus (HIV)
History of Grade 2 CNS hemorrhage or history of any CNS hemorrhage within 28 days of study entry
Female patients who are pregnant or lactating. Pregnant or lactating women will not be entered on this study because there is no available information regarding human fetal or teratogenic toxicities
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note